Fortress Biotech (FBIO) Cash from Operations Growth (1y) (2011 - 2025)
Powered by 
Analysis
Fortress Biotech (FBIO) Cash from Operations Growth (1y) (2011 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 42.76% |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 75.58% |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 151.70% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 100.14% |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 56.79% |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.81% |
| Sep 30, 2025 | 69.54% |
| Jun 30, 2025 | -26.20% |
| Mar 31, 2025 | 22.94% |
| Dec 31, 2024 | 63.05% |
| Sep 30, 2024 | -19.55% |
| Jun 30, 2024 | 34.40% |
| Mar 31, 2024 | 41.26% |
| Dec 31, 2023 | 26.98% |
| Sep 30, 2023 | 61.23% |
| Jun 30, 2023 | 19.63% |
| Mar 31, 2023 | 7.77% |
| Dec 31, 2022 | -23.64% |
| Sep 30, 2022 | -99.45% |
| Jun 30, 2022 | -20.21% |
| Mar 31, 2022 | -116.06% |
| Dec 31, 2021 | -88.89% |
| Sep 30, 2021 | 9.19% |
| Jun 30, 2021 | -97.91% |
| Mar 31, 2021 | 0.93% |